$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000114420417026058 Filed on May 10, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$4.404M	$2.778M	$660.0K
YoY Change	97.49%	320.91%	32.0%
Cost Of Revenue	$878.0K	$469.0K
YoY Change	170.99%
Gross Profit	$3.526M	$2.309M
YoY Change	84.99%
Gross Profit Margin	80.06%	83.12%
Selling, General & Admin	$11.13M	$10.25M	$7.930M
YoY Change	28.94%	29.28%	127.22%
% of Gross Profit	315.77%	444.0%
Research & Development	$1.800M	$8.404M	$7.736M
YoY Change	-12.62%	8.63%	371.13%
% of Gross Profit	51.05%	363.97%
Depreciation & Amortization	$180.0K	$682.0K	$4.000K
YoY Change	119.51%	16950.0%	-33.33%
% of Gross Profit	5.1%	29.54%
Operating Expenses	$73.89M	$62.26M	$15.75M
YoY Change	325.49%	295.27%	25.3%
Operating Profit	-$25.50M	-$19.13M	-$15.57M
YoY Change	49.6%	22.82%	23.86%
Interest Expense	$1.380M	$698.0K	$620.0K
YoY Change	160.87%	12.58%	87.31%
% of Operating Profit
Other Income/Expense, Net	$244.0K	$3.015M	-$1.552M
YoY Change	-119.47%	-294.27%	234.48%
Pretax Income	-$22.95M	-$14.56M	-$16.64M
YoY Change	40.02%	-12.5%	32.7%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$17.37M	-$11.98M	-$12.21M
YoY Change	39.16%	-1.83%	1.24%
Net Earnings / Revenue	-394.3%	-431.32%	-1849.24%
Basic Earnings Per Share
Diluted Earnings Per Share	-$428.4K	-$296.8K	-$307.9K
COMMON SHARES
Basic Shares Outstanding	50.33M shares	50.32M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$167.8M	$135.2M	$81.40M
YoY Change	135.34%	66.09%	11.69%
Cash & Equivalents	$161.2M	$150.9M	$81.42M
Short-Term Investments	$23.40M	$1.200M
Other Short-Term Assets	$12.90M	$9.500M	$1.600M
YoY Change	706.25%	493.75%	128.57%
Inventory	$299.0K	$204.0K
Prepaid Expenses
Receivables	$3.336M	$1.400M
Other Receivables	$5.900M	$5.400M
Total Short-Term Assets	$190.2M	$151.8M	$84.30M
YoY Change	148.28%	80.07%	21.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.329M	$7.400M	$2.600M
YoY Change	62.87%	184.62%
Goodwill	$18.65M	$18.65M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$300.0K	$300.0K	$250.0K
YoY Change	20.0%	20.0%	0.0%
Other Assets	$16.30M	$16.30M	$15.00M
YoY Change	11.64%	8.67%	-3.85%
Total Long-Term Assets	$59.62M	$60.10M	$20.60M
YoY Change	177.79%	191.75%	-1.44%
TOTAL ASSETS
Total Short-Term Assets	$190.2M	$151.8M	$84.30M
Total Long-Term Assets	$59.62M	$60.10M	$20.60M
Total Assets	$249.8M	$211.9M	$104.9M
YoY Change	154.74%	102.0%	15.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$25.00M	$24.90M	$2.300M
YoY Change	390.2%	982.61%	228.57%
Accrued Expenses	$12.37M	$11.12M	$7.800M
YoY Change	45.56%	42.56%	47.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$6.200M	$5.300M
YoY Change
Total Short-Term Liabilities	$53.50M	$52.80M	$10.80M
YoY Change	274.13%	388.89%	83.05%
LONG-TERM LIABILITIES
Long-Term Debt	$40.70M	$27.80M	$20.80M
YoY Change	86.7%	33.65%	-13.33%
Other Long-Term Liabilities	$5.026M	$5.000M	$2.400M
YoY Change	35.84%	108.33%	700.0%
Total Long-Term Liabilities	$5.026M	$32.80M	$23.20M
YoY Change	-80.29%	41.38%	-4.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$53.50M	$52.80M	$10.80M
Total Long-Term Liabilities	$5.026M	$32.80M	$23.20M
Total Liabilities	$99.23M	$164.2M	$60.30M
YoY Change	58.26%	172.31%	99.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$274.6M
YoY Change
Common Stock	$800.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$72.27M	$47.70M	$44.57M
YoY Change
Total Liabilities & Shareholders Equity	$249.8M	$211.9M	$104.9M
YoY Change	154.69%	102.0%	15.91%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$17.37M	-$11.98M	-$12.21M
YoY Change	39.16%	-1.83%	1.24%
Depreciation, Depletion And Amortization	$180.0K	$682.0K	$4.000K
YoY Change	119.51%	16950.0%	-33.33%
Cash From Operating Activities	-$23.88M	-$11.48M	-$11.64M
YoY Change	223.58%	-1.42%	509.42%
INVESTING ACTIVITIES
Capital Expenditures	-$190.0K	$261.0K	$2.293M
YoY Change	-91.2%	-88.62%
Acquisitions		$4.626M
YoY Change
Other Investing Activities	-$20.03M	-$680.0K	-$210.0K
YoY Change	872.33%	223.81%	-97.02%
Cash From Investing Activities	-$20.23M	-$942.0K	-$2.700M
YoY Change	379.38%	-65.11%	-67.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$34.20M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	54.42M	$58.16M	-2.430M
YoY Change	3480.26%	-2493.42%	-125.96%
NET CHANGE
Cash From Operating Activities	-23.88M	-$11.48M	-11.64M
Cash From Investing Activities	-20.23M	-$942.0K	-2.700M
Cash From Financing Activities	54.42M	$58.16M	-2.430M
Net Change In Cash	10.31M	$45.74M	-16.77M
YoY Change	-202.28%	-372.77%	1896.43%
FREE CASH FLOW
Cash From Operating Activities	-$23.88M	-$11.48M	-$11.64M
Capital Expenditures	-$190.0K	$261.0K	$2.293M
Free Cash Flow	-$23.69M	-$11.74M	-$13.93M
YoY Change	353.83%	-15.77%	629.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	2105000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	136000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-11982000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-12205000	USD
CY2016Q1	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-918000	USD
CY2017Q1	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	1030000	USD
CY2016Q4	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	1030000	USD
CY2017Q1	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	2858000	USD
CY2016Q4	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	3357000	USD
CY2017Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1528000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1712000	USD
CY2017Q1	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	1206000	USD
CY2016Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	2357000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	204000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	203000	USD
CY2017Q1	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1034000	USD
CY2016Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1790000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	18645000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	18645000	USD
CY2017Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24864000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23871000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10190000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11940000	USD
CY2017Q1	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	943000	USD
CY2016Q4	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	995000	USD
CY2017Q1	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue	1000	USD
CY2016Q4	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue	298000	USD
CY2017Q1	fbio	Warrants Issuable Current WarrantsIssuableCurrent	10096000	USD
CY2016Q4	fbio	Warrants Issuable Current WarrantsIssuableCurrent	14359000	USD
CY2017Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	96000	USD
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	77000	USD
CY2016Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1000000	USD
CY2017Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3147000	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1031000	USD
CY2017Q1	fbio	Contingently Issuable Liabilities Current ContingentlyIssuableLiabilitiesCurrent	0	USD
CY2016Q4	fbio	Contingently Issuable Liabilities Current ContingentlyIssuableLiabilitiesCurrent	1682000	USD
CY2017Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	244000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	319000	USD
CY2017Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1637000	USD
CY2016Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	3656000	USD
CY2017Q1	us-gaap	Sales Revenue Net SalesRevenueNet	44682000	USD
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	660000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	62259000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	15751000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15091000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	75000	USD
CY2017Q1	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-668000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3015000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1552000	USD
CY2017Q1	us-gaap	Profit Loss ProfitLoss	-14562000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-16643000	USD
CY2017Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2580000	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4438000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40357711	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39658188	shares
CY2017Q1	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	698000	USD
CY2016Q1	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	620000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4342000	USD
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	89000	USD
CY2017Q1	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-97000	USD
CY2016Q1	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	0	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	2929000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	206000	USD
CY2017Q1	fbio	Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance	0	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	246000	USD
CY2016Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	369000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2929000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2866000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-4000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1832000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11475000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-11637000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	261000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2293000	USD
CY2017Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2016Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	200000	USD
CY2017Q1	fbio	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	-30000	USD
CY2016Q1	fbio	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	-48000	USD
CY2017Q1	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	3000	USD
CY2016Q1	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	0	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-942000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2703000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-635000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	166000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1882000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	169000	USD
CY2017Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	2000	USD
CY2016Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2016Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	35000	USD
CY2017Q1	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	665000	USD
CY2016Q1	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	35000	USD
CY2017Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	1265000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	682000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	133000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-462000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2017Q1	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-756000	USD
CY2016Q1	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	1158000	USD
CY2017Q1	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	USD
CY2016Q1	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	175000	USD
CY2017Q1	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	201000	USD
CY2016Q1	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	0	USD
CY2017Q1	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	-52000	USD
CY2016Q1	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	0	USD
CY2017Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	115000	USD
CY2016Q1	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2017Q1	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	-4342000	USD
CY2016Q1	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	89000	USD
CY2017Q1	fbio	Change In Fair Value Of Contingent Consideration Payable ChangeInFairValueOfContingentConsiderationPayable	7000	USD
CY2017Q1	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	-499000	USD
CY2016Q1	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	0	USD
CY2017Q1	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	17000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	0	USD
CY2017Q1	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	-1151000	USD
CY2016Q1	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	0	USD
CY2017Q1	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	-297000	USD
CY2016Q1	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	0	USD
CY2017Q1	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	30000	USD
CY2016Q1	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	0	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	58000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	77000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	27498000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	4889000	USD
CY2017Q1	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash Deposites With Clearing Organizations BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashDepositesWithClearingOrganizations	1030000	USD
CY2017Q1	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Receivable From Brokers Dealers And Clearing Agencies BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivableFromBrokersDealersAndClearingAgencies	1607000	USD
CY2017Q1	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Securities Owned Fair Value BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecuritiesOwnedFairValue	2178000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	1985000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	1132000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	353000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	75817000	USD
CY2017Q1	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Compensation Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationPayable	14029000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	6079000	USD
CY2017Q1	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Clearing And Marketing Credits BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredClearingAndMarketingCredits	1007000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	707000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	35228000	USD
CY2017Q1	us-gaap	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue	17717000	USD
CY2017Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest	22872000	USD
CY2017Q1	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrants Issuable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantsIssuable	13406000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	176000	USD
CY2016Q1	us-gaap	Depreciation Depreciation	4000	USD
CY2014Q1	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
CY2014Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.35	pure
CY2016Q4	fbio	Equity Securities Called By Warrant EquitySecuritiesCalledByWarrant	10000	USD
CY2017Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1294000	USD
CY2016Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	83000	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	35575000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	30224000	USD
CY2017Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2549000	USD
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50332002	shares
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	623000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	424000	USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	58160000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2009000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	698000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	620000	USD
CY2017Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3532000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2846000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1450000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1253000	USD
CY2017Q1	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	680000	USD
CY2016Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	394000	USD
CY2017Q1	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	900000	USD
CY2016Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	900000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1874000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2002000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11120000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10082000	USD
CY2017Q1	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	0	USD
CY2017Q1	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2684000	USD
CY2016Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2634000	USD
CY2017Q1	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	5020000	USD
CY2016Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	5014000	USD
CY2016	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	60668000	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-16195000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14510348	shares
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11131304	shares
CY2017Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2929000	USD
CY2016Q1	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2866000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1130501	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1130501	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1105501	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.73
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.73
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.71
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1216285000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y11M5D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y8M8D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y7M28D
CY2017Q1	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	35000	USD
CY2016Q1	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	27000	USD
CY2017Q1	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2017Q1	us-gaap	Revenues Revenues	44682000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	469000	USD
CY2017Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2267000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8404000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7985000	USD
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Trading Symbol TradingSymbol	FBIO
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-2427000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	45743000	USD
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50319919	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50319919	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48932023	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48932023	shares
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-16767000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	205000	USD
CY2017Q1	fbio	Payment Of Nsc Note PaymentOfNscNote	0	USD
CY2016Q1	fbio	Payment Of Nsc Note PaymentOfNscNote	2792000	USD
CY2017Q1	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	3254000	USD
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 31.9pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	19000	USD
CY2016Q1	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	55904000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	570000	USD
CY2017Q1	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	2998000	USD
CY2016Q1	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
CY2017Q1	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	2000000	USD
CY2016Q1	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	0	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98182000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	81415000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15991000	USD
CY2017Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	408000	USD
CY2017Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15583000	USD
CY2017Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	746000	USD
CY2017Q1	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	746000	USD
CY2017Q1	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	5186000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0193	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0222	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.0398	pure
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.0595	pure
CY2017Q1	fbio	Annual Management Services Agreement Fee Incomeexpense AnnualManagementServicesAgreementFeeIncomeexpense	0	USD
CY2016Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	53000	USD
CY2017Q1	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	81151000	USD
CY2017Q1	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	100000	USD
CY2017Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.566	pure
CY2017Q1	fbio	Warrants Issued WarrantsIssued	853677	shares
CY2017Q1	fbio	Percentage Of Shares Issued To Placement Agent PercentageOfSharesIssuedToPlacementAgent	0.1	pure
CY2017Q1	fbio	Cash And Cash Equivalents Acquired From Business Combination CashAndCashEquivalentsAcquiredFromBusinessCombination	27498000	USD
CY2017Q1	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	22872000	USD
CY2017Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4626000	USD
CY2017Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2000	USD
CY2017Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	158000	USD
CY2016Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2017Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	4000	USD
CY2016Q1	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
CY2016Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2017Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	206000	USD
CY2017Q1	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	1682000	USD
CY2016Q1	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	0	USD
CY2017Q1	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	1712000	USD
CY2017Q1	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	52906000	USD
CY2017Q1	fbio	Adjustments To Additional Paid In Capital Debt Discount Related To Opus Credit Facility AdjustmentsToAdditionalPaidInCapitalDebtDiscountRelatedToOpusCreditFacility	158000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	20941000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-668000	USD
CY2017Q1	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	-4342000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	97000	USD
CY2017Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	16028000	USD
CY2017Q1	us-gaap	Equity Method Investments EquityMethodInvestments	300000	USD
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	300000	USD
CY2017Q1	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	700000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	602451000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1216285000	USD
CY2017Q1	us-gaap	Notes Payable NotesPayable	33026000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	28215000	USD

Files In Submission

Name	View Source	Status
0001144204-17-026058-index-headers.html	Edgar Link	pending
0001144204-17-026058-index.html	Edgar Link	pending
0001144204-17-026058.txt	Edgar Link	pending
0001144204-17-026058-xbrl.zip	Edgar Link	pending
fbio-20170331.xml	Edgar Link	completed
fbio-20170331.xsd	Edgar Link	pending
fbio-20170331_cal.xml	Edgar Link	unprocessable
fbio-20170331_def.xml	Edgar Link	unprocessable
fbio-20170331_lab.xml	Edgar Link	unprocessable
fbio-20170331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v466104_10q.htm	Edgar Link	pending
v466104_ex10-33.htm	Edgar Link	pending
v466104_ex10-34.htm	Edgar Link	pending
v466104_ex10-35.htm	Edgar Link	pending
v466104_ex10-36.htm	Edgar Link	pending
v466104_ex10-37.htm	Edgar Link	pending
v466104_ex31-1.htm	Edgar Link	pending
v466104_ex31-2.htm	Edgar Link	pending
v466104_ex32-1.htm	Edgar Link	pending
v466104_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2017 Q2 Form 10-Q Financial Statement

#000114420417026058 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2017 Q2 Form 10-Q Financial Statement

#000114420417026058 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio